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Summary The effect of 3-week, preoperative tamoxifen treatment on oestrogen receptor (ER) levels, expressed by primary breast tumours,
was examined. Patients (age-matched) with breast cancer, confirmed by fine-needle aspiration, were either treated with 20 mg ml-' oral
tamoxifen per day or received no medication in the 3-week interval between assessment and surgery. Quantification of ER using flow
cytometry was performed on the surgically removed tumour samples from tamoxifen-treated (n = 40) and control (n = 38, untreated) patient
groups. The tumours were mechanically disaggregated, and saponin treatment rendered these cells permeable to antibodies. Using dual-
parameter labelling with a FITC-conjugated antibody (NCL-5D3) directed against cytokeratin 8/18/19 and a biotinylated antibody (DAKO-ER
1D5) directed against the oestrogen receptor, ER quantification was determined on a number of receptors per cell basis. Using QC quantum
bead standards, ER levels in the epithelial cell population, the non-epithelial cell population and the whole-cell population (ER +) were
calculated. ER levels were significantly lower in the total cell population than tamoxifen-treated patients (P = 0.002) when compared with the
control (untreated) group. By using a gating procedure using 5D3 antibody positivity, a significantly lower level was detected on examining the
cytokeratin-positive population alone (P = 0.006). Using a complementary gating technique, ER levels were quantified in the cytokeratin-
negative cell population. Examination of this group of cells showed no significant difference between the levels of oestrogen receptor found in
the tamoxifen-treated and untreated groups (P = 0.4). We have demonstrated that ER levels can be monitored by flow cytometry. ER levels
in patients treated with tamoxifen 3 weeks before operation are significantly lower than in a comparative group of patients who received no
drug. Furthermore, the most significant difference in receptor levels is seen by quantification of total ER levels expressed by all the tissue.
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Binding of hormones to the oestrogen receptor (ER) results in
formation of a stabilized complex that interacts with specific
regions of DNA (Yamamato and Alberts, 1976). This leads to
increased transcription of hormone-dependent genes, translation
into proteins and eventually replication, and tumour cell division
and growth. In human breast cancer, ER has been associated with
superior prognosis (Howell et al, 1984) and a greater likelihood of
response to endocrine therapy on relapse.
Tamoxifen is a commonly used anti-oestrogen that functions by
interacting with hormone receptors (Nomura et al, 1985; Sawka et
al, 1986). Adjuvant tamoxifen increases relapse-free survival and
overall survival for patients with resectable breast cancer (Early
Breast Cancer Trialist's Collaborative Group, 1992). Its role as a
systemic treatment for primary operable breast cancer has been well
documented and is summarized by Richards et al (1994). It is well
established that tamoxifen treatment decreases ER levels (Lacobelle
et al, 1986); however, short-term treatment has been reported to
increase ER levels (Wesada et al, 1988; Horwitz et al, 1978),
although these findings have been disputed (Montoya et al, 1992).
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With the availability of monoclonal antibodies directed against
the oestrogen receptor, quantification ofER by flow cytometry has
been demonstrated (Brotherick et al, 1995). The flow-cytometric
method has been shown to compare favourably with the radio-
ligand-binding assay (P = 1 x 10-5) usually used to detect ER in
breast tumours. The monoclonal antibody DAKO-ER 1D5, which
reacts with the N-terminal domain (A/B region) of the receptor
(Kumar et al, 1987), has been shown to give a good correlation
immunohistochemically with results obtained by biochemical
quantification (Schutte et al, 1992).
As ER is closely associated with the nucleus, cell permeabiliza-
tion to ER 1D5 antibody is necessary. Furthermore, a method of
ER calibration must be used. We have reported the use ofa method
to quantify epidermal growth factor receptor (EGF R) expression
on both primary breast tumours and cell lines (Brotherick et al,
1994), and have used this in a slightly modified form to examine
ER status.
Flow cytometry offers the ability to use multiparametric
analysis to examine cell populations within the tumour and quan-
tify ER expression within these groups. Using the monoclonal
antibody NCL-5D3, which reacts with cytokeratins 8, 18 and 19
(Angus et al, 1987), we can define cytokeratin-positive and
-negative populations within the tumour and examine ER levels.
Monitoring preoperative oestrogen levels could be used in the
clinical situation to identify those patients responding to tamoxifen
treatment, as well as identifying those who have not responded.
Therapy could be altered accordingly.
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The aim of this study was to examine ER levels in breast
tumours ofpatients treated with 20 mg ml tamoxifen for 3 weeks
before operation. Oestrogen receptor levels were examined on the




Mycoplasma-screened adherent breast tumour cell lines MCF7
(ER+control), and peripheral blood mononuclear cells (PBMC
negative control) were used to confirm ER staining, as previously
reported (Brotherick et al, 1995), using the same method as for
primary breast tissue.
Patients and treatment
Patients with confirmed breast cancer were administered tamox-
ifen at 20 mg ml-' per day for 3 weeks or received no drug before
operation.
Preparation of primary breast tumour tissue
Breast cancer samples were obtained post-operation from patients
treated or untreated with tamoxifen. Following operation an
unfixed, tumour sample identified macroscopically by the patholo-
gist and confirmed as tumour (not less than 80% tumour) micro-
scopically, was snap-frozen and stored at-80°C. The sample was
finely minced, further disaggregated by passing through a fine wire
mesh (approximately 50 Htm) to form a single-cell suspension.
ER assessment by flow cytometry
The suspensions of primary tumour cells (approximately 1 x 106
cells ml-' Isoton II) were aliquoted into 50-tl samples in LPIO
tubes (SH Scientific, Northumberland, UK). To each sample 50,ul
of 2% saponin (BDH, in Isoton II) was added with gentle
mixing. Ten microlitres of cytokeratin 5D3 FITC (Novocastra
Laboratories, Newcastle upon Tyne, UK) and 2.5 ,tl of biotin-
conjugated anti-ER antibody (DAKO A/S) was then added to each
tumour to be tested. Further samples of each cell suspension were
stained with S ,ul of MsIgG-2b-FITC isotype control (Coulter)
or with 10gl of streptavidin-phycoerythrin (SA-PE, BD). All
samples were incubated at 4°C for 20 min and then washed with
Isoton II containing I% saponin. To those cells labelled with ER
1D5 (DAKO A/S), 10gl of SA-PE (BD) was added to the cell
pellet as described previously. After incubation and washing, the
cell pellet was resuspended in 0.5 ml of Isoton II and flow cyto-
metry was performed on a FACScan flow cytometer (BD) using
prestored settings (Brotherick et al, 1995). Ten thousand cells
(debris was excluded by threshold) were collected. Data analysis
was performed using Lysis II software. Cytokeratin-positive or
-negative cells were gated, and median fluorescence (PE) values
determined from the FL2 histogram for SA-PE-stained (control)
and ER-stained cells. Binding capacities were evaluated from
the standardized QSC bead equation (QSC, Flow Cytometry
Standards corporation, NC, USA) as previously described
(Brotherick et al, 1995). Data were calculated as the number of
oestrogen receptors (determined as the test sample minus the
control level).
Statistical analysis
Statistical analysis was performed using SPSS PC program to
perform the Mann-Whitney U-test and generate 95% confidence
intervals.
RESULTS
MCF7 cells showed positive labelling with ER 1D5 and lympho-
cytes demonstrated only background levels of autofluorescence,
confirming antibody specificity.
The levels ofER were measured on 40 tamoxifen-treated and 38
untreated patient breast cancers. Levels of ER were examined on
the total cell population without using a gating protocol (Figure
IB). Using a cytokeratin gate (RI, Figure 1A) the level of ER was
determined on the cytokeratin-positive population (Figure 1C).
The percentage cytokeratin-positive cells was not less than 50% of
the total cells run, and the average per cent cytokeratin-positive
cells was 78%. Using a second gate (R2, Figure IA) ER levels
were determined on the cytokeratin-negative cell population
(Figure 1D).
Examination of ER levels in the total cell population showed a
median value of 37 540 (95% confidence interval 31 867-45 359,
n = 38) ER per cell in the untreated population. In the tamoxifen-
treated population, a mean value of 23 350 (95% confidence
interval 18 534-29 391, n = 40) ER per cell was seen. The
Mann-Whitney U-test showed a significantly lower level of ER
expression in the tamoxifen-treated group (P = 0.002, Figure 2).
Examination of ER levels in the cytokeratin-positive cell popu-
lation showed a median value of 46 000 (95% confidence interval
34 365-55 570, n = 38) ER per cell in the untreated population. In
the tamoxifen-treated population, a mean value of 19 108 (95%
confidence interval 18 990-34 196, n = 40) ER per cell was seen.
The Mann-Whitney U-test showed a significantly lower level of
ER expression in the tamoxifen-treated group (P = 0.006, Figure 2).
Examination of ER levels in the total cell population showed a
median value of 22 647 (95% confidence interval 20 545-28 301,
n = 38) ER per cell in the untreated population. In the tamoxifen-
treated population, a median value of 20 381 (95% confidence
interval 18 358-25 384, n = 40) ER per cell was seen. The
Mann-Whitney U-test showed no significant difference in the
level of ER expression in the tamoxifen group compared with the
untreated group (P = 0.4, Figure 2).
DISCUSSION
Oestrogen receptor status has been reported to be of prognostic
value (Howell et al, 1984); however, more recently its value for
prognosis and therapeutic response has been disputed (Maki and
Hoehn, 1989) and the limitations of the oestrogen receptor assay
reported (Poulsen, 1981). In the paper by Cohen et al (1988) image
cytometry has been reported to allow both quantitation and exam-
ination of heterogeneous tumours. In our paper we report the use
ofER 1D5 antibody in conjunction with an cx-cytokeratin antibody
to quantify the ER status of primary breast cancers by flow
cytometry without the need for fixation and prolonged incubation
(Brotherick et al, 1995).
The short-term treatment of breast cancer with tamoxifen has
been reported to increase ER levels (Horwitz et al, 1978; Waseda
et al, 1981). Although high ER levels are prognostically good,
treatment with tamoxifen should block the oestrogen receptor.
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Figure 1 Figure 1 illustrates the gates used to examine ER expression on cytokeratin-positive and cytokeratin-negative populations. A illustrates the
cytokeratin-positive (Rl) and -negative (R2) gates. B illustrates a histogram of fluorescence (ER) for the total cell population, C for the cytokeratin-positive gated
cells and D for the cytokeratin-negative population.
Therefore, rises in ER levels in tamoxifen-treated patients preoper-
atively could elicit a stimulatory effect in non-responding cells, i.e.
cause proliferation of phenotypes associated with poor prognosis.
It would be useful to confirm ER status shortly before operation to
determine if tamoxifen treatment has an effect in the 3-week
period before operation and after diagnosis.
Long-term tamoxifen treatment decreases ER levels (Lacobelle
et al, 1986), and indeed in the short term some findings confirm
decreased ER levels (Montoya et al, 1992). Our findings concur
with those of Montoya et al (1992), with significant falls in ER
levels reported in those patients treated with tamoxifen 3 weeks
before operation. Interestingly, some ER expression is seen in the
cytokeratin-negative population and may reflect ER levels in
fibroblasts. These levels are also seen to fall, although not signifi-
cantly, with tamoxifen treatment. It may be important to examine
this cell population as cytokeratin-negative tumour cells could
theoretically be present. Logical progression ofthe research would
be to compare pre- and post-tamoxifen samples from the same
patient using fine-needle aspiration samples. Ethical permission
and the need to perform an invasive procedure are points that will
need addressing and were determining factors in this study when
pre-tamoxifen sampling was not performed.
We conclude that use of flow cytometric analysis of ER is a
rapid, reliable and quantifiable methodology that can be applied to
monitoring receptor levels in pre-operative tamoxifen-treated
patients.
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Figure 2 Figure 2 illustrates the number of ER molecules per cell in tamoxifen-treated or untreated breast cancer patients. Three groups have been
compared: FZ, ER expression in the cytokeratin-positive population; Z, cytokeratin-negative population; 1, in the total population (error bars = s.e.m., n = 40
(tamoxifen+) and n = 38 (tamoxifen-)
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